论文部分内容阅读
本文对我院儿科6年来收治的97例小儿急性淋巴细胞白血病（ALL）进行临床总结和分析，初治57例，复治40。初治组中43例采用VDLP方案进行诱导缓解，完全缓解（CR）率为100％，复发率为6．9％（3／43），2例为骨髓复发，l例为睾丸白血病复发，无中枢神经系统复发。未采用VDLP方案诱导缓解的另14例初治病人CR率为75％。复治组中VDLP再诱导缓解的CR率为69．2％。非VDLP再诱导缓解的CR率为46．7％。本资料表明采用VDLP是提高CR率的关键，病初白细胞计数和肝脾肿大程度是诱导缓解的影响因素，CR所需时间长短与预后有明显关系，治疗过程中积极处理合并症是提高生存率的重要因素，本资料提示是否近年来ALL－L2有增多趋势，有待进一步观察。
97 cases of pediatric acute lymphoblastic leukemia (ALL) admitted to our hospital for 6 years were summarized and analyzed. Among them, 57 cases were initially treated and 40 cases were retreated. In the newly diagnosed group, 43 cases were treated with VDLP regimen. The complete remission (CR) rate was 100%, the recurrence rate was 6.9% (3/43), two cases of bone marrow recurrence, one case of testicular leukemia recurrence, Central nervous system recurrence. The CR rate of another 14 newly diagnosed patients who did not use VDLP regimen to induce remission was 75%. The CR rate of re-induced VDLP in retreatment group was 69.2%. The CR rate of non-VDLP re-induced remission was 46.7%. The data show that the use of VDLP is the key to improve the CR rate, disease early white blood cell count and degree of hepatosplenomegaly induction of remission factors, the length of time required for CR has a clear relationship with the prognosis, aggressive treatment of complications in the course of treatment is to improve survival An important factor in the rate, this data suggests whether there is an increasing trend of ALL-L2 in recent years, pending further observation.